» Articles » PMID: 32873534

Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers

Overview
Publisher Elsevier
Specialty Oncology
Date 2020 Sep 3
PMID 32873534
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Isolation of malignant plasma cells from bone marrow of patients with monoclonal gammopathies is critical for studies into the disease biology. The plasma cells are typically isolated by positive selection using plasma cell markers such as CD138. Here we have examined the effect of CD138 magnetic bead selection on the expression of other surface phenotypic markers on plasma cells.

Materials And Methods: Bone marrow aspirates from 16 patients were split and prepared using 2 methods before staining for flow cytometric evaluation. The first method (whole bone marrow) used an ammonium-chloride-potassium lyse of whole bone marrow followed by 2 phosphate buffered saline washes. The second method used CD138-positive magnetic sorting technology (Stem Cell Technology). The cells were run on the FACSCanto flow cytometer after staining for CD38, CD45, CD56, activation markers CD71, CD69, CD154, adhesion markers CD49d, CD49e, CD11a, CD11b, and CD66, B cell markers CD19 and CD20, and for clonality.

Results: There was a substantial loss in the expression of CD71, CD11b, CD11a, CD69, and CD49e on plasma cells following CD138-based sorting. Moreover, in 8 of the 16 cases, there was a nearly complete loss of the CD45-positive subset with a loss of discrimination between CD45-negative and CD45-positive plasma cell subsets in the remaining CD138-sorted preparations.

Conclusions: The change in immunophenotype of the plasma cells on magnetic sorting should be kept in mind when isolating plasma cells using CD138-positive selection for analysis of plasma cells. The technique for characterizing plasma cells should be selected based on the study design to prevent loss of crucial and valuable information.

Citing Articles

Combined replacement of lnc-MEG3 and miR-155 elicit tumor suppression in multiple myeloma.

El-Khazragy N, Abdelrahman S, Darwish A, Hemida E Epigenomics. 2025; 17(3):167-177.

PMID: 39815805 PMC: 11816889. DOI: 10.1080/17501911.2025.2453413.


Investigating the effect of immunomagnetic separation on the immunophenotype and viability of plasma cells in plasma cell disorders.

Czeti A, Sashalmi S, Takacs F, Szaloki G, Kriston C, Varga G Pathol Oncol Res. 2024; 30:1611882.

PMID: 39493694 PMC: 11527611. DOI: 10.3389/pore.2024.1611882.


Hypoxia-related prognostic model in bladder urothelial reflects immune cell infiltration.

Li L, Liu W, Tang H, Wang X, Liu X, Yu Z Am J Cancer Res. 2021; 11(10):5076-5093.

PMID: 34765313 PMC: 8569353.

References
1.
. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-57. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

3.
Matsui W, Huff C, Wang Q, Malehorn M, Barber J, Tanhehco Y . Characterization of clonogenic multiple myeloma cells. Blood. 2003; 103(6):2332-6. PMC: 3311914. DOI: 10.1182/blood-2003-09-3064. View

4.
Kumar S, Kimlinger T, Morice W . Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010; 23(3):433-51. PMC: 3005703. DOI: 10.1016/j.beha.2010.09.002. View

5.
Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi J . The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998; 100(4):637-46. DOI: 10.1046/j.1365-2141.1998.00623.x. View